-+ 0.00%
-+ 0.00%
-+ 0.00%

SueWallSt Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN

Barchart·08/06/2026 09:07:00
Listen to the news

Institutional investors with REGN positions may need to assess alleged clinical-trial disclosure failures that preceded a $102.09 per-share decline from the Class Period high. This notice focuses on fiduciary review, portfolio loss documentation, and lead plaintiff considerations.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.